Figure 3. MPS determines sex-specific morbidity and mortality. (A) MPS males were more likely to die prematurely than any other group (at 14-15 months). (B) Midlife premature death in MPS males was linked to higher disease risk for renal failure, heart and respiratory disease and tumors. (C) Life expectancy with 530 days maximum endpoint. Asterisks indicate significances: *p<0.05, **p<0.01, ***p<0.001, “c” indicates survival probability of MPS males vs. MPS females age 14-15 (*), 16 (**) and 17-18 months (**). Male CONTROL n=10, male MPS n=12, female CONTROL n=14, female MPS n=14.